Multivariable logistic regression model assessing factors associated with severe infections in patients diagnosed with NHL
| Variable . | OR . | 95% CI . | P value . |
|---|---|---|---|
| IgG testing∗ | |||
| No IgG testing | Reference | ||
| 1 | 0.44 | (0.39-0.50) | <.0001† |
| 2 | 0.38 | (0.31-0.46) | <.0001† |
| ≥3 | 0.14 | (0.12-0.16) | <.0001† |
| IgRT use∗ | 0.62 | (0.39-0.992) | .046† |
| Rituximab-based regimens‡ | 2.61 | (2.39-2.85) | <.0001† |
| Targeted therapy‡ | 3.35 | (2.88-3.89) | <.0001† |
| Neutropenia§ | 8.0 | (7.11-8.90) | <.0001† |
| Diabetes§ | 2.42 | (2.16-2.70) | <.0001† |
| Sinusitis§ | 1.74 | (1.49-2.04) | <.0001† |
| Bronchitis§ | 2.69 | (2.23-3.25) | <.0001† |
| Age | <.0001† | ||
| 18-64 | Reference | ||
| ≥65 | 1.26 | (1.16-1.37) | <.0001† |
| Sex | |||
| Male | Reference | ||
| Female | 0.87 | (0.80-0.95) | .002† |
| Variable . | OR . | 95% CI . | P value . |
|---|---|---|---|
| IgG testing∗ | |||
| No IgG testing | Reference | ||
| 1 | 0.44 | (0.39-0.50) | <.0001† |
| 2 | 0.38 | (0.31-0.46) | <.0001† |
| ≥3 | 0.14 | (0.12-0.16) | <.0001† |
| IgRT use∗ | 0.62 | (0.39-0.992) | .046† |
| Rituximab-based regimens‡ | 2.61 | (2.39-2.85) | <.0001† |
| Targeted therapy‡ | 3.35 | (2.88-3.89) | <.0001† |
| Neutropenia§ | 8.0 | (7.11-8.90) | <.0001† |
| Diabetes§ | 2.42 | (2.16-2.70) | <.0001† |
| Sinusitis§ | 1.74 | (1.49-2.04) | <.0001† |
| Bronchitis§ | 2.69 | (2.23-3.25) | <.0001† |
| Age | <.0001† | ||
| 18-64 | Reference | ||
| ≥65 | 1.26 | (1.16-1.37) | <.0001† |
| Sex | |||
| Male | Reference | ||
| Female | 0.87 | (0.80-0.95) | .002† |
Patients diagnosed with NHL: n = 13 232.
For patients having an infection, IgG testing and IgRT use were measured in the 12 months before the date of infection.
P < .05 were considered to be significant.
Assessed at any time point because dates are not available in the clinical notes.
Clinical conditions were assessed at any time point.